JPS5611436B2 - - Google Patents

Info

Publication number
JPS5611436B2
JPS5611436B2 JP11842677A JP11842677A JPS5611436B2 JP S5611436 B2 JPS5611436 B2 JP S5611436B2 JP 11842677 A JP11842677 A JP 11842677A JP 11842677 A JP11842677 A JP 11842677A JP S5611436 B2 JPS5611436 B2 JP S5611436B2
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP11842677A
Other languages
Japanese (ja)
Other versions
JPS5452794A (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to JP11842677A priority Critical patent/JPS5452794A/ja
Priority to US05/947,103 priority patent/US4197290A/en
Priority to GB7838618A priority patent/GB2009771B/en
Priority to FR7828133A priority patent/FR2410043A1/fr
Publication of JPS5452794A publication Critical patent/JPS5452794A/ja
Priority to FR8022285A priority patent/FR2468372A1/fr
Publication of JPS5611436B2 publication Critical patent/JPS5611436B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/823—Bacterial vaccine for bovine species, e.g. cattle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP11842677A 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus Granted JPS5452794A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP11842677A JPS5452794A (en) 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus
US05/947,103 US4197290A (en) 1977-09-30 1978-09-29 Vaccine
GB7838618A GB2009771B (en) 1977-09-30 1978-09-29 Vaccine
FR7828133A FR2410043A1 (fr) 1977-09-30 1978-10-02 Nouveau vaccin contre la mammite de la vache et son procede de production
FR8022285A FR2468372A1 (fr) 1977-09-30 1980-10-17 Nouveau vaccin contre les maladies infectieuses chez les bovins et son procede de production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11842677A JPS5452794A (en) 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus

Publications (2)

Publication Number Publication Date
JPS5452794A JPS5452794A (en) 1979-04-25
JPS5611436B2 true JPS5611436B2 (enExample) 1981-03-14

Family

ID=14736342

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11842677A Granted JPS5452794A (en) 1977-09-30 1977-09-30 Extracting of polysacchride from capusle containing epidermis staphylococus

Country Status (4)

Country Link
US (1) US4197290A (enExample)
JP (1) JPS5452794A (enExample)
FR (2) FR2410043A1 (enExample)
GB (1) GB2009771B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62165286U (enExample) * 1986-04-07 1987-10-20

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327082A (en) * 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
US4425330A (en) 1981-05-20 1984-01-10 Cornell Research Foundation, Inc. Bovine mastitis vaccine and method for detecting efficacy thereof
US4762712A (en) * 1983-08-31 1988-08-09 Stolle Research & Development Corporation Anti-mastitis polyvalent vaccine, method of administration and method for production thereof
DE3345864A1 (de) * 1983-12-19 1985-06-27 Egbert Frh. von 8000 München Malsen-Ponickau Impfstoff und verfahren zu seiner herstellung
FR2619122B1 (fr) * 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US5034515A (en) * 1987-09-22 1991-07-23 Wisconsin Alumni Research Foundation Staphylococcal fibronectin receptor, monoclonal antibodies thereto and methods of use
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US7279162B1 (en) * 1990-10-22 2007-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection
US20080139789A1 (en) * 1990-10-22 2008-06-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine Isolated Broadly Reactive Opsonic Immunoglobulin for Treating a Pathogenic Coagulase-Negative Staphylococcus Infection
US5955074A (en) * 1990-10-22 1999-09-21 Henry M. Jackson Foundation For The Advancement Of Military Medicine Directed human immune globulin for the prevention and treatment of staphylococcal infections
AU681573B2 (en) * 1991-11-22 1997-09-04 Glaxosmithkline Biologicals Sa Type I and type II surface antigens associated with (staphylococcus epidermidis)
US5980908A (en) * 1991-12-05 1999-11-09 Alfa Laval Ab Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment
EP0628056A4 (en) * 1992-02-25 1997-03-05 Jackson H M Found Military Med TARGETED HUMAN IMMUNGLOBULINE TO PREVENT AND TREAT STAPHYLOCOCCEN INFECTIONS.
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
EP1583517B1 (en) 2002-11-12 2019-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
NZ539153A (en) 2002-11-12 2006-11-30 Brigham & Womens Hospital Polysaccharide vaccine for staphylococcal infections
US7786255B2 (en) 2004-04-21 2010-08-31 The Bringham and Women's Hospital, Inc. Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
NZ591103A (en) 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
JP2012504660A (ja) 2008-10-06 2012-02-23 ユニバーシティ オブ シカゴ 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法
RU2403283C2 (ru) * 2008-12-30 2010-11-10 Общество с ограниченной ответственностью "БиоМедВет" Штамм staphylococcus epidermidis bvm-1987 - продуцент стафилолитического ферментного комплекса
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
US9060965B2 (en) 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
CN103917245B (zh) 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
EP3735268A4 (en) * 2018-01-05 2021-12-22 Azitra, Inc. AUXOTROPICAL STRAINS OF STAPHYLOCOCCUS BACTERIA
WO2020163512A1 (en) 2019-02-05 2020-08-13 The Brigham And Women's Hospital, Inc. Polysaccharide compositions for use in treating filariasis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL278429A (enExample) * 1900-01-01
NL262599A (enExample) * 1900-01-01
GB925124A (en) * 1960-03-21 1963-05-01 Parke Davis & Co Staphylococcal vaccine
DE1154234B (de) * 1960-03-21 1963-09-12 Parke Davis & Co Verfahren zur Herstellung einer Staphylococcenvaccine
FR1334930A (fr) * 1961-03-20 1963-08-16 Parke Davis & Co Procédé de production d'un antigène nouveau par extraction de culture de staphylocoques
DK105490C (da) * 1961-05-15 1966-10-03 Parke Davis & Co Fremgangsmåde til fremstilling af et stafylokok-antigenprodukt i form af immunogene polysaccharidforbindelser.
US3269913A (en) * 1962-05-11 1966-08-30 Parke Davis & Co Staphylococcal-immunizing products and methods for their production
GB995338A (en) * 1963-09-20 1965-06-16 Parke Davis & Co Polysaccharides and methods for their production
JPS5520268B2 (enExample) * 1972-07-15 1980-05-31

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62165286U (enExample) * 1986-04-07 1987-10-20

Also Published As

Publication number Publication date
FR2410043B1 (enExample) 1983-09-09
FR2410043A1 (fr) 1979-06-22
GB2009771B (en) 1982-07-14
FR2468372B1 (enExample) 1983-10-14
JPS5452794A (en) 1979-04-25
US4197290A (en) 1980-04-08
GB2009771A (en) 1979-06-20
FR2468372A1 (fr) 1981-05-08

Similar Documents

Publication Publication Date Title
FR2410043B1 (enExample)
DE2857901A1 (enExample)
FR2377915B1 (enExample)
FR2378094B2 (enExample)
FR2378161B1 (enExample)
FR2378010B1 (enExample)
FR2376912B3 (enExample)
FR2378212B1 (enExample)
FR2378206B2 (enExample)
FR2378124B1 (enExample)
DE7734063U1 (enExample)
FR2376932B3 (enExample)
FR2367205B2 (enExample)
DK585278A (enExample)
DK180777A (enExample)
FR2377821B1 (enExample)
DK367677A (enExample)
BG25851A1 (enExample)
BG25837A1 (enExample)
BG25855A1 (enExample)
BG25853A1 (enExample)
BG25852A1 (enExample)
CH604409A5 (enExample)
BG25850A1 (enExample)
BG25848A1 (enExample)